BMY · News · 20260805N
AI Drug Discovery Collaboration
BRISTOL MYERS SQUIBB CO · 2026-08-05 · Importance 31 · Surprise 42 · In source text
Bristol Myers Squibb agreed with Schrödinger to deploy the Bunsen agentic AI co-scientist across BMS research operations. The collaboration expands BMS's use of Schrödinger's computational platform to support molecular exploration and drug-discovery decision-making. The parties will co-develop additional Bunsen functionality and integrate it with Schrödinger's RetroSynth AI synthesis-planning platform.
Key facts
- Schrödinger announced a strategic agreement with Bristol Myers Squibb to integrate Bunsen, Schrödinger's agentic AI co-scientist, into BMS's research operations. source
- The Schrödinger-Bristol Myers agreement involves co-development of new functionalities within Bunsen and integration with RetroSynth, Schrödinger's AI-driven synthesis planning platform. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | probable | — | The Schrödinger-Bristol Myers agreement involves co-development of new functionalities within Bunsen and integration with RetroSynth,… |